GLG Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GLG Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$2.29M	Buy	26,933 +6,816	+34%	+$571K	0.11%	211
2017 Q3	$1.74M	Buy	+20,117	New	+$1.61M	0.09%	202
2017 Q1	–	Sell	-5,076	Closed	-$300K	–	529
2016 Q4	$300K	Sell	5,076 -100,920	-95%	-$6.23M	0.01%	335
2016 Q3	$7.03M	Sell	105,996 -88,394	-45%	-$5.47M	0.22%	134
2016 Q2	$10.5M	Buy	194,390 +189,762	+4,100%	+$10.4M	0.31%	97
2016 Q1	$239K	Buy	+4,628	New	+$240K	0.01%	374

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

GLG Partners's XBI Position: Q4 2017 in Review

GLG Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 34% in Q4 2017, buying an estimated $571K and bringing the position to 26,933 shares worth $2.29M. The position accounts for 0.11% of the portfolio, ranked #211.

GLG Partners first reported a position in XBI in Q1 2016 and has held it in 6 quarters since. The position peaked at $10.5M in Q2 2016. 397 funds tracked by Wall St. Rank hold XBI as of Q4 2017.

GLG Partners held 26,933 shares of State Street SPDR S&P Biotech ETF worth $2.29M as of Q4 2017.
GLG Partners bought 6,816 State Street SPDR S&P Biotech ETF shares in Q4 2017, an estimated $571K.
State Street SPDR S&P Biotech ETF made up 0.11% of GLG Partners's portfolio in Q4 2017, its #211 holding.
GLG Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 6 quarters since.
GLG Partners's State Street SPDR S&P Biotech ETF position peaked at $10.5M in Q2 2016.
397 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.